The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016
Open accessAbstract
The overall objective of the guidelines is to provide up‐to‐date, evidence‐based recommendations for the diagnosis and management of the full spectrum of Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS–TEN overlap in adults during the acute phase of the disease. The document aims to: (i) offer an appraisal of all relevant literature up to February 2016, focusing on any key developments; (ii) address important, practical clinical questions relating to the primary guideline objective, i.e. accurate diagnosis and identification of cases and suitable treatment; (iii) provide guideline recommendations; and (iv) discuss areas of uncertainty, potential developments and future directions SJS/TEN is rare and few healthcare professionals are confident in the recognition and management of the disorder. There is widely divergent practice among different specialities and healthcare settings, and limited information on outcomes. These guidelines aim to provide recommendations on the diagnosis and management of SJS/TEN, to inform clinical decision‐making and, when justified by evidence, to standardize practice. The breadth of this document should be sufficient to assist clinicians of all relevant specialities in the management of patients with SJS/TEN. The recommendations will also inform pathways of care to optimize healthcare delivery and highlight key areas of uncertainty for future research. In these guidelines, the term SJS/TEN encompasses the full spectrum of the disease, i.e. SJS, TEN and SJS–TEN overlap (see section section 10 for clinical definition of the separate entities). The guideline is presented as a detailed review with highlighted recommendations for practical use (see section section 64), in addition to the development of a new patient information leaflet [available on the British Association of Dermatologists’ (BAD) website, www.bad.org.uk]. Unless otherwise specified, recommendations apply to all forms of the disease. This guideline does not cover paediatric patients. An addendum to this guideline addressing the needs of paediatric patients with SJS/TEN is planned. The evidence for treatment of children differs from that of adult patients, and will be considered separately. The management of long‐term sequelae of SJS/TEN is not considered in this document. The guideline development group (GDG) consisted of consultant dermatologists (D.C., S.A.W., H.Y.L., J.S., C.B.B., M.R.A.‐J., K.M.T.W., G.A.E.W., C.H.S.), including oral (J.S.) and urogenital specialists (S.A.W., C.B.B.), a histopathologist (M.P.), burns/plastic surgeon specialists (P.D., G.W., M.S.), a burns anaesthestist (R.V.M.), intensive care specialists (A.V., R.V.M.), an ophthalmologist (J.K.G.D.), a dermatological clinical nurse specialist (D.B.) and a patient (P.W.). The draft document went out for consultation to the BAD membership, British Dermatological Nursing Group, Primary Care Dermatological Society, British Burn Association, British Association of Plastic, Reconstructive and Aesthetic Surgeons, Royal College of Ophthalmologists, Association of Anaesthetists of Great Britain and Ireland, Intensive Care Society and SJS Awareness U.K. The comments received were actively considered by the GDG. Following further review, the amended draft was recirculated to the stakeholders for comments and the finalized version peer‐reviewed by the Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines Subcommittee) prior to publication. This set of guidelines has been developed using the BAD's recommended methodology,1 and with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument (www.agreetrust.org).2 Recommendations were developed for implementation in the National Health Service using a process of considered judgement based on the evidence. A series of specific questions was developed within the scope of the guideline; for each question, PubMed, MEDLINE and Embase, and the Cochrane Library were searched for meta‐analyses, randomized and nonrandomized controlled clinical trials, open studies and case series to February 2016. The literature was searched for evidence to address the questions. The search terms and strategies are detailed online (Data S1; see Supporting Information). Additional relevant references were also isolated from citations in the reviewed literature, as well as specific targeted searches for hypersensitivity testing, causative drugs, diagnostic and prognostic indicators, topical treatments, oral/mouth, growth factors and granulocyte colony‐stimulating factor (G‐CSF), and analgesia. The lead authors screened the identified titles, and those relevant for first‐round inclusion were selected for further scrutiny. All co‐authors then reviewed the abstracts for the shortlisted references and the full papers of relevant material were obtained; disagreements in the final selections were resolved by discussion with the entire GDG. In section section 47, active inte
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
ESPEN guidelines on parenteral nutrition: intensive care
Singer, P., Berger, M. M., Van den Berghe, G., Biolo, G., Calder, P., Forbes, A., Griffiths, R., Kreyman, G., Leverve, X., & Pichard, C. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2009.04.024 · Cited by 1,907
Bastuji‐Garin, S. (1993) · Archives of Dermatology · doi:10.1001/archderm.129.1.92 · Cited by 1,697
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
ESPEN guidelines on enteral nutrition: intensive care
Kreymann, K. G., Berger, M. M., Deutz, N. E. P., Hiesmayr, M., Jolliet, P., Kazandjiev, G., Nitenberg, G., van den Berghe, G., Wernerman, J., Ebner, C., et al. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.01.021 · Cited by 1,366
SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Fouchard, N., Bertocchi, M., Roujeau, J.-C., Revuz, J., Wolkenstein, P., & Bastuji-Garin, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00061.x · Cited by 1,199
Mockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Cited by
Severe cutaneous adverse reactions to drugs
Duong, T. A., Valeyrie-Allanore, L., Wolkenstein, P., & Chosidow, O. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30378-6 · Cited by 445
Current perspectives on severe drug eruption
Zhang, J., Lei, Z., Xu, C., Zhao, J., & Kang, X. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08859-0 · Cited by 60
Metadata
- Authors
- Creamer, D., Walsh, S. A., Dziewulski, P., Exton, L. S., Lee, H. Y., Dart, J. K. G., Setterfield, J., Bunker, C. B., Ardern‐Jones, M. R., Watson, K. M. T., Wong, G. A. E., Philippidou, M., Vercueil, A., Martin, R. V., Williams, G., Shah, M., Brown, D., Williams, P., Mohd Mustapa, M. F., Smith, C. H., McHenry, P. M., Hughes, J. R., Griffiths, M., Gibbon, K., McDonagh, A. J., Buckley, D. A., Nasr, I., Swale, V. J., Duarte Williamson, C. E., Levell, N. J., Leslie, T., Mallon, E., Wakelin, S., Ungureanu, S., Hunasehally, P., Cork, M., Towers, K., Donnelly, J., Saunders, C., & Brain, A. G.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06
- Volume
- 174
- Issue
- 6
- Pages
- 1194-1227
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2419735139
- Cited by
- 277
- References
- 66
- FWCI
- 19.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. https://app.cochat.ai/papers/10.1111/bjd.14530
- The paper
- Creamer, D., Walsh, S. A., Dziewulski, P., Exton, L. S., Lee, H. Y., Dart, J. K. G., Setterfield, J., Bunker, C. B., Ardern‐Jones, M. R., Watson, K. M. T., Wong, G. A. E., Philippidou, M., Vercueil, A., Martin, R. V., Williams, G., Shah, M., Brown, D., Williams, P., Mohd Mustapa, M. F., . . . Brain, A. G. (2016). U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. British Journal of Dermatology. https://doi.org/10.1111/bjd.14530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.